Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hPMSC-derived exosomes for anastomotic leakage in rectal cancer
NCT06536712Phase 1Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of Human placenta mesenchymal stem cell-derived exosomes in rectal cancer (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Number of patients with early anastomotic leakage at 1 month. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Human placenta mesenchymal stem cell-derived exosomes
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06536712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536712.